Cocrystal Pharma appoints James Sapirstein as CEO, replacing co-CEOs Sam Lee and Jim Martin

Cocrystal Pharma, Inc.

James Sapirstein appointed CEO effective June 3, 2026, replacing Sam Lee and Jim Martin as co-CEOs.
Sam Lee becomes President and Chief Scientific Officer; Jim Martin remains CFO.
Sapirstein has led 23 product launches and served as CEO of Contravir and Tobira Therapeutics.
Company plans to appoint Sapirstein to the Board of Directors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.